BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22033412)

  • 61. Hematopoietic stem cells are not the direct target of spontaneous leukemic transformation in p18(INK4C)-null reconstituted mice.
    Yuan Y; Yu H; Boyer MJ; Song X; Cao S; Shen H; Cheng T
    Cancer Res; 2006 Jan; 66(1):343-51. PubMed ID: 16397248
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
    Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
    Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.
    Wolf S; Rudolph C; Morgan M; Büsche G; Salguero G; Stripecke R; Schlegelberger B; Baum C; Modlich U
    Oncogene; 2013 Jun; 32(25):3028-38. PubMed ID: 22847614
    [TBL] [Abstract][Full Text] [Related]  

  • 64. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
    Masamoto Y; Chiba A; Mizuno H; Hino T; Hayashida H; Sato T; Bando M; Shirahige K; Kurokawa M
    Blood Adv; 2023 Apr; 7(8):1577-1593. PubMed ID: 36269819
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
    Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
    Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.
    Jo A; Mitani S; Shiba N; Hayashi Y; Hara Y; Takahashi H; Tsukimoto I; Tawa A; Horibe K; Tomizawa D; Taga T; Adachi S; Yoshida T; Ichikawa H
    Leukemia; 2015 May; 29(5):1076-83. PubMed ID: 25567132
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.
    Yuasa H; Oike Y; Iwama A; Nishikata I; Sugiyama D; Perkins A; Mucenski ML; Suda T; Morishita K
    EMBO J; 2005 Jun; 24(11):1976-87. PubMed ID: 15889140
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The role of EVI1 in normal and leukemic cells.
    Buonamici S; Chakraborty S; Senyuk V; Nucifora G
    Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
    [TBL] [Abstract][Full Text] [Related]  

  • 69. EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.
    Wilson M; Tsakraklides V; Tran M; Xiao YY; Zhang Y; Perkins AS
    J Biol Chem; 2016 Jun; 291(26):13591-607. PubMed ID: 27129260
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
    Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
    PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases].
    Fuchs O
    Cas Lek Cesk; 2006; 145(8):619-24. PubMed ID: 16995417
    [TBL] [Abstract][Full Text] [Related]  

  • 72. EVI1 up-regulates the stress responsive gene SIRT1 which triggers deacetylation and degradation of EVI1.
    Pradhan AK; Kuila N; Singh S; Chakraborty S
    Biochim Biophys Acta; 2011; 1809(4-6):269-75. PubMed ID: 21555002
    [TBL] [Abstract][Full Text] [Related]  

  • 73. EVI1 induces autophagy to promote drug resistance via regulation of ATG7 expression in leukemia cells.
    Niu Y; Yang X; Chen Y; Jin X; Li L; Guo Y; Li X; Xie Y; Zhang Y; Wang H
    Carcinogenesis; 2020 Jul; 41(7):961-971. PubMed ID: 31593983
    [TBL] [Abstract][Full Text] [Related]  

  • 74. EVI1 drives leukemogenesis through aberrant ERG activation.
    Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
    Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
    Tanaka A; Nakano TA; Nomura M; Yamazaki H; Bewersdorf JP; Mulet-Lazaro R; Hogg S; Liu B; Penson A; Yokoyama A; Zang W; Havermans M; Koizumi M; Hayashi Y; Cho H; Kanai A; Lee SC; Xiao M; Koike Y; Zhang Y; Fukumoto M; Aoyama Y; Konuma T; Kunimoto H; Inaba T; Nakajima H; Honda H; Kawamoto H; Delwel R; Abdel-Wahab O; Inoue D
    Blood; 2022 Aug; 140(8):875-888. PubMed ID: 35709354
    [TBL] [Abstract][Full Text] [Related]  

  • 76. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
    Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1.
    Volkert S; Schnittger S; Zenger M; Kern W; Haferlach T; Haferlach C
    Cancer Genet; 2014 Mar; 207(3):103-8. PubMed ID: 24726268
    [TBL] [Abstract][Full Text] [Related]  

  • 78. EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
    Saito Y; Sawa D; Kinoshita M; Yamada A; Kamimura S; Suekane A; Ogoh H; Matsuo H; Adachi S; Taga T; Tomizawa D; Osato M; Soga T; Morishita K; Moritake H
    Haematologica; 2020 Aug; 105(8):2118-2129. PubMed ID: 31649131
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A critical role of epigenetic inactivation of miR-9 in EVI1
    Mittal N; Li L; Sheng Y; Hu C; Li F; Zhu T; Qiao X; Qian Z
    Mol Cancer; 2019 Feb; 18(1):30. PubMed ID: 30813931
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Expression of EVI1 in Bone Marrow of Patients with AML and ALL and Its Correlation with Leukemia Subtyping, Clinical Features and Prognosis of Patients].
    Peng DH; Liu J; Hu HN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1323-1329. PubMed ID: 30295245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.